Our data suggested that N.S supplementation had significant impacts on liver and kidney parameters leading to a decrease in ALP and BUN levels .
The aim of this systematic review and dose-response meta- analysis was to determine the effect of Nigella Sativa ( N.S ) supplementation on  liver and kidney parameters .
Effects of Nigella sativa on outcome of hepatitis C in Egypt.
AIM To evaluate the safety , efficacy and tolerability of Nigella sativa ( N. sativa ) in patients with hepatitis C not eligible for interferon (IFN)-α . METHODS Thirty patients with hepatitis C virus ( HCV ) infection , who were not eligible for IFN/ribavirin therapy , were included in the present study . Inclusion criteria included : patients with HCV with or without cirrhosis , who had a contraindication to IFN-α therapy , or had refused or had a financial constraint to IFN-α therapy . Exclusion criteria included : patients on IFN-α therapy , infection with hepatitis B or hepatitis I virus , hepatocellular carcinoma , other malignancies , major severe illness , or treatment non-compliance . Various parameters , including clinical parameters , complete blood count , liver function , renal function , plasma glucose , total antioxidant capacity ( TAC ) , and polymerase chain reaction , were all assessed at baseline and at the end of the study . Clinical assessment included : hepato and /or splenomegaly , jaundice , palmar erythema , flapping tremors , spider naevi , lower-limb edema , and ascites . N. sativa was administered for three successive months at a dose of ( 450 mg three times daily ) . Clinical response and incidence of adverse drug reactions were assessed initially , periodically , and at the end of the study . RESULTS N. sativa administration significantly improved HCV viral load ( 380808.7 ± 610937 vs 147028.2 ± 475225.6 , P = 0.001 ) and TAC ( 1.35 ± 0.5 vs 1.612 ± 0.56 , P = 0.001 ) . After N. sativa administration , the following laboratory parameters improved : total protein ( 7.1 ± 0.7 vs 7.5 ± 0.8 , P = 0.001 ) , albumin ( 3.5 ± 0.87 vs 3.69 ± 0.91 , P = 0.008 ) , red blood cell count ( 4.13 ± 0.9 vs 4.3 ± 0.9 , P = 0.001 ) , and platelet count ( 167.7 ± 91.2 vs 198.5 ± 103 , P = 0.004 ) . Fasting blood glucose ( 104.03 ± 43.42 vs 92.1 ± 31.34 , P = 0.001 ) and postpr and ial blood glucose ( 143.67 ± 72.56 vs 112.1 ± 42.9 , P = 0.001 ) were significantly decreased in both diabetic and non-diabetic HCV patients . Patients with lower-limb edema decreased significantly from baseline compared with after treatment [ 16 ( 53.30 % ) vs 7 ( 23.30 % ) , P = 0.004 ] . Adverse drug reactions were unremarkable except for a few cases of epigastric pain and hypoglycemia that did not affect patient compliance . CONCLUSION N. sativa administration in patients with HCV was tolerable , safe , decreased viral load , and improved oxidative stress , clinical condition and glycemic control in diabetic patients
Our data suggested that N.S supplementation had significant impacts on liver and kidney parameters leading to a decrease in ALP and BUN levels .
The aim of this systematic review and dose-response meta- analysis was to determine the effect of Nigella Sativa ( N.S ) supplementation on  liver and kidney parameters .